The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 Criteria

Mitotic figure (MF) counting is the most objective criterion for grading of meningiomas according to the 2000 World Health Organization (WHO) classification. However, the search for the area(s) of highest mitotic activity is tedious, and there is high interobserver variability in differentiating MF from apoptotic cells. We tested the utility of the mitosis-specific marker phosphohistone-H3 (PHH3) to enhance rapid recognition of MFs and quick reliable grading of meningioma. Fifty-four archival meningiomas (26 benign, 20 atypical, 8 anaplastic) were reclassified according to current WHO criteria. PHH3-immunostained MFs were counted the same way as in hematoxylin and eosin-stained sections. Anti-PHH3-labeled MFs were easily seen and permitted quick identification of the area(s) of highest mitotic activity. Count results (mean) show a strong correlation between both methods: benign, hematoxylin and eosin 1.4, PHH3 2.2; atypical, hematoxylin and eosin 9.0, PHH3 15.9; anaplastic, hematoxylin and eosin 22.4, PHH3 34.1. PHH3 counting yielded greater sensitivity and in 12 cases (22.2%) suggested a change in grade (increased 9; lowered 3). All cases in which PHH3 lowered the grade were from older blocks, suggesting a loss of antigen preservation. PHH3 immunostaining facilitates the rapid reliable grading of meningiomas by focusing attention on the most mitotically active areas and by allowing easy and objective differentiation of MFs from apoptotic nuclei.

[1]  M. Møller,et al.  No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry , 1997, Journal of Neuro-Oncology.

[2]  K. Hess,et al.  Aggressive meningeal tumors: review of a series. , 1995, Journal of neurosurgery.

[3]  Hsu,et al.  MIB‐1(Ki‐67) index and transforming growth factor‐alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas , 1998, Neuropathology and applied neurobiology.

[4]  C. Allis,et al.  Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation , 1997, Chromosoma.

[5]  W. Poon,et al.  Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas. , 1998, Human pathology.

[6]  J. A. D'Anna,et al.  Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. , 1978, European journal of biochemistry.

[7]  J. Jääskeläinen,et al.  Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. , 1986, Surgical neurology.

[8]  C. Allis,et al.  Chromatin Condensation Is Not Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[9]  Z. Darżynkiewicz,et al.  Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. , 1998, Cytometry.

[10]  L. Langford,et al.  Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. , 1996, Human pathology.

[11]  R. Prayson,et al.  MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. , 1998, Human pathology.

[12]  R. Prayson.  Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. , 1996, American journal of clinical pathology.

[13]  大田 正流.  MIB1 staining index and scoring of histologic features in meningioma , 1995 .

[14]  B. Scheithauer,et al.  The prognostic significance of MIB‐1, p53, and DNA flow cytometry in completely resected primary meningiomas , 1998, Cancer.

[15]  B. Scheithauer,et al.  "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. , 1999, Cancer.

[16]  A. Asai,et al.  Postoperative residual tumor growth of meningioma can be predicted by MIB‐1 immunohistochemistry , 1999, Cancer.

[17]  Y. Takeshima,et al.  Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. , 2001, Human pathology.

[18]  R. Kiss,et al.  Characterization of Nuclear DNA Content, Proliferation Index, and Nuclear Size in a Series of 181 Meningiomas, Including Benign Primary, Recurrent, and Malignant Tumors , 1993, The American journal of surgical pathology.

[19]  B. Scheithauer,et al.  Meningioma grading: an analysis of histologic parameters. , 1997, The American journal of surgical pathology.

[20]  R. Prayson.  Cell Proliferation and Tumors of the Central Nervous System Part 1: Evaluation of Mitotic Activity , 2002, Journal of neuropathology and experimental neurology.

[21]  G. Fuller.  Pathology and Genetics of Tumours of the Nervous System (World Health Organization Classification of Tumours). , 2001 .

[22]  Masayuki Nakajima,et al.  Significance of MIB-1 Staining Indices in Meningiomas: Comparison of Two Counting Methods , 2001, The American journal of surgical pathology.

[23]  M. Fukui,et al.  MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management , 1994, Cancer.

[24]  A. Asai,et al.  Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas , 1996, Acta Neuropathologica.